Compare Organon & Co. Common Stock (OGN) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Valero Energy Corporation — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Valero Energy Corporation trades at $461.01 (market cap $131.43B). The key difference: Valero Energy Corporation is far larger — about 36.3× Organon & Co. Common Stock's market cap, and Valero Energy Corporation pays the higher dividend (1.05%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Valero Energy Corporation for 57 Days on average.
| OGN | VLO | |
|---|---|---|
Market Cap | $3.62B | $131.43B |
Volume | 2,892,999 | 2,513,030 |
Sector | Health | Energy |
52-Week High | $13.81 | $459.78 |
52-Week Low | $5.70 | $156.39 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $11.04B | $134.90B |
Dividend Yield | 0.58% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Valero Energy (VLO) trades at $459.78, up 5.45% today, near its 52-week high. The stock exhibits strong bullish momentum with recent earnings beats and positive technical signals. Revenue declined to $122.69B in 2025, but net income margin improved to 5.17%. Analyst consensus is bullish with a 56.76% buy rating, though the current price exceeds the $408.10 consensus target. Recent news highlights institutional inflows and refining margin strength.
Outlook is positive due to earnings momentum and favorable sector trends, but risks include potential policy impacts on diesel exports and high valuation multiples. The stock's proximity to resistance at $460 suggests near-term consolidation may occur. Long-term growth depends on sustaining refining margins and cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
